An EHR-embedded inpatient care pathway for COPD was tied to improved adherence to evidence-based practices, shorter hospital ...

Dr. Rojas-Quintero is researching how Metformin, a long-used diabetes drug, may be able to slow fibrosis in the lungs.

COPD is not reversible; however, it can be controlled. Increased awareness, spirometry testing, and encouraging healthier ...

COPD mortality in China decreased from 2014 to 2021, but the disease burden remains high in underdeveloped regions. COPD is mainly caused by air pollution and smoking, with older adults being the most ...

Nicholas Hill, MD, Chair of the CHEST-initiated COPD technical expert panel In 2021, CHEST organized and led technical expert ...

Dr MeiLan Han, of the University of Michigan, Ann Arbor, highlights studies in chronic obstructive pulmonary disease (COPD) presented at the CHEST 2021 Annual Meeting. Dr Han first reports on a study ...

Christopher Carlin, MB ChB, PhD, explores the potential of AI-driven insights to enhance COPD care and identify candidates for biologic therapy.

The global asthma and COPD drugs market size was US$ 34522.6 million in 2021. The global asthma and COPD drugs market size is forecast to reach US$ 53049.54 million by 2030, growing at a compound ...

Inhalers Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations. Single-inhaler ...

Eosinophil Granulocytes COPD Patients with COPD who exhibit low blood eosinophil counts had no change in exacerbations or survival compared with patients with typical counts. Patients with chronic ...